Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 12, 2013, Pages 2137-2147

  Semeraro, F ^a   Ammollo, C T ^a   Gils, A ^b   Declerck, P J ^b   Colucci, M ^a  

^a UNIVERSITY OF BARI   (Italy)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Fibrinolysis; Inflammation; Plasmin; Thrombin; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

COMPLEMENT COMPONENT C5A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TCK11A9; MONOCLONAL ANTIBODY TCK26D6; MYELOPEROXIDASE; OSTEOPONTIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOT LYSIS; CELL ADHESION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FIBRINOLYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING;

FIBRINOLYSIS; INFLAMMATION; PLASMIN; THROMBIN; THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANTIBODIES, MONOCLONAL; CARBOXYPEPTIDASE U; COMPLEMENT C5A; FIBRINOLYSIS; HUMANS; OSTEOPONTIN;

EID: 84889690829     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12431     Document Type: Article

References (28)

1. Declerck PJ. Thrombin activatable fibrinolysis inhibitor. Hamostaseologie 2011; 31: 165-73.
2. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1: 2000-7.
3. Guimarães AH, Barrett-Bergshoeff MM, Criscuoli M, Evangelista S, Rijken DC. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI). Thromb Haemost 2006; 96: 325-30.
4. Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency. J Thromb Haemost 2012; 10: 2555-62.
5. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
6. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B - modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-52.
7. Semeraro F, Piro D, Rossiello MR, Ammollo T, Colucci M. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thromb Haemost 2007; 98: 1208-14.
8. Ammollo CT, Semeraro F, Semeraro N, Colucci M. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins. Thromb Haemost 2009; 101: 782-5.
9. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8: 790-8.
10. Miah MF, Boffa MB. Functional analysis of mutant variants of thrombin activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin. J Thromb Haemost 2009; 7: 665-72.
11. Binette TM, Taylor FB Jr, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007; 110: 3168-75.
12. Leurs J, Wissing B-M, Nerme V, Schatteman K, Bijorquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-71.
13. Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A. Identification and characterization of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011; 106: 90-101.
14. Vercauteren E, Mutch NJ, Declerck PJ, Gils A. Plasmin and the thrombin-thrombomodulin complex both contribute to TAFI activation in whole blood model thrombi. J Thromb Haemost 2013; 11: 190-2.
15. Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils A. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood 2011; 117: 4615-22.
16. Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-96.
17. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
18. Ceresa E, De Maeyer M, Jonckheer A, Peeters M, Engelborghs Y, Declerck PJ, Gils A. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. J Thromb Haemost 2007; 5: 2105-12.
19. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-61.
20. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
21. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ. Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3: 2745-53.
22. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
23. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
24. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
25. Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 661-6.
26. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
27. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
28. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation. Thromb Res 2012; 129: 314-19.